Investment ThemesDetailed Quotes
CAR-T Therapy
Watchlist
- 1068.619
- +9.216+0.87%
Close Apr 29 16:00 ET
1077.400High1052.263Low
1058.743Open1059.403Pre Close128.33MVolume7Rise27.01P/E (Static)5.38BTurnover--Flatline0.91%Turnover Ratio1.11TMarket Cap3Fall1.09TFloat Cap
Constituent Stocks: 10Top Rising: PFE+3.21%
Tonight, the stock will try to reclaim 24 level.
The stock finally breaks above 24. If the price can stay above 24, the uptrend momentum will be sustainable.
Big green candle. Next resistance is 24.10. Once it breaks the resistance, next hit point will be 24.28. The stock is trading above 5 EMA, 10 EMA and 20 EMA but below 60 EMA. The trend is up and bullish.
$Pfizer (PFE.US)$'s stock rose Tuesday after the drug manufacturer said it's trending toward the higher end of its 2025 profit projections.
Pfizer also beat analyst expectations for first-quarter earnings as it benefited from cost-saving efforts, although it fell short of Wall Street's revenue estimate, as sales of its COVID-19 medicine Paxlovid plunged by 75% on fading demand.
"Our focus on operational efficiency and financial discipline is driving strong results to our bottom l...
Earnings Per Share (EPS):Analysts generally expect Q1 EPS to be slightly lower than the same period last year.For the US-listed ADS (American Depositary Shares), consensus estimates range from approximately $1.04 to $1.0...
Breakthrough: Pfizer's New Bladder Cancer Treatment First Major Advance in 30 Years - See 91% Success Rate
Pfizer (PFE) announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with standard of care Bacillus Calmette-Guerin as induction therapy with or without maintenance in patients with BCG-naive, high-risk non-muscle invasive bladder cancer, NMIBC. The trial met its primary endpoint of event-free survival, EFS, by investigator assessment, demonstrating a clinically meaningful and statistically significan...
No comment yet